Advertisements

Zolpidem Teva

Quick links to important sections

Zolpidem Teva

Selected form

Advertisements
Advertisements

Treatment option: Insomnia, Polysomnography

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Zolpidem Teva

Quick Facts Description
Active ingredient Zolpidem tartrate
Form Film-coated tablet (Oral solid form)
Pharmacological class Sedative-hypnotic agent (Z-drug)
General purpose Promote sleep onset
Origin Synthetic imidazopyridine derivative

What Type of Medicine is Zolpidem Teva?

Zolpidem Teva is a prescription-only medicine classified as a sedative-hypnotic agent, belonging to the group of nonbenzodiazepine receptor modulators, widely recognized as Z-drugs. The active chemical substance is Zolpidem (INN), a synthetic compound categorized as an Imidazopyridine derivative. Zolpidem Teva is typically manufactured as a generic formulation, distinguishing it as a bioequivalent product to the original reference medicine.

This classification means the drug is clinically recognized for its targeted effect on the central nervous system to induce sedation. The drug's unique feature is its preferential binding to a specific subunit of the GABAA receptor complex, which allows for a rapid onset of hypnotic action, primarily aimed at achieving a sleep state efficiently.


Composition and General Purpose

The product is a single-agent formulation containing Zolpidem tartrate, the stabilized salt form of the active substance. Zolpidem Teva is supplied as an oral solid form, typically a film-coated tablet, intended for the oral route of administration. The tablet comprises the active ingredient alongside necessary pharmaceutical excipients.

The general purpose of Zolpidem Teva is to provide a targeted solution for short-term difficulties initiating sleep, such as in cases of transient insomnia. Its action is focused on promoting sleep and efficiently reducing the time it takes to fall asleep. The medicine's effect is fundamentally limited to the induction of a sleep-like state, a critical function for patients experiencing severely distressed sleep patterns.

Regulatory References

  1. Zolpidem - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Zolpidem Teva?

Possible side effects and safety information

Official regulatory documentation classifies the possible side effects of Zolpidem Teva by incidence and the affected System-Organ Class (SOC). This information is derived from clinical studies and post-marketing surveillance, providing a structured view of the medicine's risk profile.

Frequency-Classified Adverse Reactions

The adverse reactions most frequently reported in official labeling are classified as Common (occurring in 1% to 10% of users). These effects often involve the nervous system and general state, including somnolence (drowsiness), headache, dizziness, and fatigue. Gastrointestinal effects like diarrhea are also listed as common. Less frequent effects are classified as Uncommon (0.1% to 1%), which include psychiatric events such as hallucination and confusional state, as well as visual disturbances like blurred vision or diplopia.

Serious Safety Concerns and Restrictions

Regulatory agencies explicitly document serious adverse reactions. These include the occurrence of Complex Sleep Behaviors (CSBs), such as sleep-driving or somnambulism, where a patient performs activities while not fully awake with no memory of the event. Severe allergic reactions, including angioedema (swelling of the tongue or throat), are also documented and considered life-threatening. The label mandates specific safety restrictions: Severe hepatic insufficiency is an absolute restriction (contraindication) due to the risk of hepatic encephalopathy. Furthermore, the use of Zolpidem Teva is restricted in patients with severe obstructive sleep apnoea or myasthenia gravis.

Population- and Time-Related Safety Patterns

Specific safety considerations apply to the older adult population, who exhibit increased sensitivity to the medicine's effects, potentially leading to a higher risk of dizziness and falls. The label also notes time-related risks: Anterograde amnesia is most likely to occur if the patient is awakened prematurely or fails to get a full night's sleep. Upon discontinuation, there is an established risk of rebound insomnia or a withdrawal syndrome.

Advertisements

Overdose and Emergency Response

Overdose Manifestations and Severity

Official regulatory documents describe an overdose of zolpidem tartrate, the active substance in Zolpidem Teva, as causing a spectrum of Impairment of consciousness. This may range from somnolence and extreme sedation to a state of light coma.

The severe outcomes documented in official labeling include Cardiorespiratory collapse and severe respiratory depression, which are recognized as potential causes of fatal outcomes. The effects often involve depression of the central nervous system (CNS) and critical impairment of the cardiorespiratory system.

Required Emergency Action and Management

Regulatory information requires individuals to seek immediate medical attention for any suspected overdose. This mandate includes contacting emergency medical services or a poison control center immediately, as the situation may be life-threatening.

Management focuses on providing symptomatic and supportive treatment. While the benzodiazepine antagonist flumazenil is noted as capable of reversing the medication's effects, the possibility of co-ingestion of multiple agents must always be considered in the management protocol. Close monitoring of vital signs is required until clinical symptoms resolve.

Population-Specific Notes

The official profile notes that elderly or debilitated patients are documented as being especially sensitive to the effects of overdose. Furthermore, regulatory documents highlight specific risks for patients with compromised respiratory function and those with severe hepatic impairment.

Advertisements

Therapeutic Uses of Zolpidem Teva

What Zolpidem Teva Treats: Main Uses and Benefits

Zolpidem Teva is generally used for the short-term symptomatic management of insomnia in adults, primarily when sleep disturbances are judged to be severe, disabling, or cause extreme distress. This medication is applied in clinical settings that involve acute or disruptive symptom patterns, offering supportive relief across key domains.

The primary therapeutic focus is to manage symptomatic manifestations related to prolonged sleep latency and frequent nocturnal awakenings. It is commonly used to help with difficulties initiating sleep, supporting sleep maintenance, and easing the overall symptom load associated with a period of severe sleeplessness.

The medication may assist with the promotion of sleep onset, which helps reduce the time spent awake and provides support that helps ease the distress associated with the nightly difficulty in sleep initiation. When symptoms noticeably interfere with functional stability, the medicine is relevant for easing acute and recurrent manifestations of sleep impairment.

“The application of this medication is reserved for sleep disturbances that present a significant symptomatic burden to the patient, requiring short-term, targeted support.”


Quick Fact: Relief for Sleep Difficulty
Primary Focus Managing symptoms related to difficulty falling asleep (sleep-onset insomnia).
Symptom Support Contributes to addressing symptom clusters like nocturnal awakenings and symptoms related to total sleep duration.
Usage Context Applied in short-term scenarios involving severe or disabling sleep disturbances in adults.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Zolpidem Teva?

The population eligibility for using Zolpidem Teva is strictly defined by government regulatory authorities based on medical condition, age, and physiological state.


Eligibility Scope

Classification Population/Condition Status
Eligible Population Adults (18 and over) for short-term use.
Absolute Contraindications Severe Hepatic Insufficiency, Severe Respiratory Insufficiency, Severe Sleep Apnoea Syndrome, Myasthenia Gravis, known Hypersensitivity to zolpidem, or prior experience of Complex Sleep Behaviors (CSBs) after zolpidem use.

Official Regulatory Rules

Age-Related Eligibility

  • Use in Children and Adolescents (under 18 years) is not recommended or contraindicated, as safety and efficacy are not established.
  • Older Adults (65 and over) are eligible, but use is conditional on a mandatory reduced starting dose.

Conditional Use Restrictions

  • Patients with Mild to Moderate Hepatic Impairment are eligible only if a reduced starting dose is prescribed.
  • Use in Pregnant Women (especially the third trimester) and during Breastfeeding is not recommended or contraindicated.
  • Patients with a history of substance abuse require extreme caution and close supervision.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Zolpidem Teva documents specific interactions that fall into pharmacodynamic, pharmacokinetic, and timing-based categories, requiring strict observance of constraints.

Formal Interaction Restrictions

Classification Interacting Substance/Product Regulatory Restriction/Note
Contraindicated Alcohol Must not be used due to enhanced central depressive effects and increased risk of complex sleep behaviors.
Use with Caution Opioids Co-administration may result in severe respiratory depression and must be reserved for patients with no alternative options.
Avoid/Not Recommended Ciprofloxacin, Fluvoxamine Concurrent use is not recommended due to potential increases in drug exposure.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions involving the metabolism of Zolpidem Teva, primarily via the CYP3A4 enzyme, alter the concentration of the drug in the body:

  • Exposure-Increasing: Substances like Ketoconazole (a strong CYP3A4 inhibitor) officially lead to an increase in Zolpidem exposure and effects.
  • Exposure-Decreasing: Rifampin (a strong CYP3A4 inducer) and the herbal product St. John's wort are documented to reduce drug exposure and decrease the overall effect.
  • Pharmacodynamic Risk: Other CNS depressants (e.g., antipsychotics, anxiolytics, and sedative antihistamines) officially enhance central depressive effects, increasing sedation and psychomotor impairment.

Administration and Population Constraints

  • Timing Rule: A period of at least 7 to 8 hours must separate drug intake from performing activities requiring mental alertness, such as driving.
  • Food Effect: Taking the medicine with or immediately after a meal may slow its effect.
  • Population Note: Patients with hepatic impairment have reduced drug clearance, and its use must be avoided in severe cases.
Advertisements

Mechanism of Action

The mechanism of Zolpidem Teva is defined by its ability to selectively amplify the brain's primary inhibitory signals, rapidly leading to a state of central nervous system ( CNS) suppression resulting in induced hypnosis.


Selective Modulation of GABA A Receptors alpha1 Subunit

Zolpidem is a Positive Allosteric Modulator that binds with high selectivity to the GABA A receptor complex, specifically targeting those containing the alpha1 subunit. This interaction potentiates the response of the GABA A receptor to the inhibitory neurotransmitter GABA, increasing the frequency of chloride ion channel opening and resulting in neuronal hyperpolarization (making the nerve cell less excitable).


Dampening of CNS Arousal Pathways

The resulting enhancement of inhibitory signaling leads to a broad dampening of high-frequency neuronal firing across the CNS. This biological cascade particularly suppresses activity in structures like the Reticular Activating System (RAS), which is responsible for maintaining alertness and wakefulness. This reduction in cortical and subcortical excitability results in the physiological consequence of rapid CNS depression and the induction of hypnosis.


Mechanistic Constraints and Selectivity Loss

The drug's mechanism is entirely contingent upon the presence of the endogenous GABA system. Its selectivity for the alpha1 subunit is a defining characteristic of the mechanism. This selectivity is dose-dependent and may lessen at higher concentrations. Furthermore, the effectiveness of the mechanism can be limited over time if the receptors undergo adaptive changes (tolerance) in response to prolonged exogenous modulation.

Advertisements

Dosage and Administration Information

How to Use Zolpidem Teva

Zolpidem Teva is an oral medicine that is administered strictly according to official guidelines, which define its use as a time-limited intervention for sleep difficulties. The medication is supplied as 5 mg and 10 mg film-coated tablets, intended for the oral route of administration.


Administration and Timing Principles

The medicine is prescribed for use on a once-daily basis, with administration required immediately before bedtime. It is a mandatory procedural constraint that the patient must have at least 7 to 8 hours of time available for sleep before the planned time of waking or performing activities that require full mental alertness. Taking the tablet with or immediately after a meal may slow the onset of its expected effects.


Dosing and Duration

The total dose of zolpidem tartrate should not exceed 10 mg per 24 hours. The recommended initial dose for women is a single 5 mg dose, while men may be started on 5 mg or 10 mg.

Official guidelines restrict use to the shortest possible duration, generally stipulating that the course of treatment, including any necessary tapering period, must not exceed four weeks. If treatment is considered necessary beyond this maximum period, a formal re-evaluation of the patient's condition is required.


Population-Specific Use

Specific dosage adjustments are mandated for certain patient populations to maintain consistency with safety profiles. The lower 5 mg dose once daily is recommended for older adults (geriatric patients) and for those diagnosed with mild-to-moderate liver (hepatic) impairment.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Zolpidem Teva


Evidence for Managing Difficulties Falling Asleep

The primary research for Zolpidem Teva has focused on research exploring short-term symptoms of sleep-onset insomnia in adults. The most significant research comes from Randomized Controlled Trials (RCTs). In these trials, groups of participants are randomly assigned to receive either the study medicine or an inactive placebo under double-blind conditions. Researchers monitored key measures related to how quickly participants fell asleep.

In these studies, research examined the change in Sleep Latency (LPS), which is the amount of time it takes to transition from being awake to entering a sleep state. Findings described patterns related to the measurements of Sleep Latency in the groups receiving the medicine during the observed short-term evaluation periods compared to those who received the placebo. This evidence contributes to understanding symptom patterns related to sleep initiation in the observed populations.


Research on Sleep Maintenance and Other Key Measures

Beyond research exploring sleep initiation, studies explored other outcomes reflecting daily functioning or activity level related to the quality of sleep itself. Researchers monitored how symptoms evolved in the observed populations by measuring whether participants had nocturnal awakenings and assessed the Total Sleep Time (TST) achieved.

The evidence derived from these settings research highlights changes measured in the amount of time participants spent awake after initially falling asleep, known as Wake After Sleep Onset (WASO). Research highlights that these changes were measured during the short-term study period, and this was observed in some studies alongside Total Sleep Time measurements that differed from baseline. While these measures were observed in studies, data related to sustained effects in sleep maintenance over the long term remains limited.


Long-term Follow-up and Duration of Evidence

Most of the available evidence concerning the medicine’s use for insomnia comes from trials with follow-up durations that were limited, typically lasting less than six weeks. Data are still emerging, and long-term effects are not fully established by extensive, controlled, multi-month trials for the immediate-release tablet form.


Studies in Specific Populations

Research was evaluated in various adult groups. Specifically, studies explored the use of the medicine in older adults (aged geq65 years). Findings related to older adult populations generally results apply only to the populations studied, often focusing on lower dose strengths.


Evidence Gaps and Areas of Uncertainty

A review of the evidence highlights several areas where certainty remains low. Comparative evidence is lacking for many common treatment scenarios, for example, limited head-to-head trials against other non-pharmacological treatments or other Z-drugs. Study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. ZOLPIDEM TARTRATE - DailyMed (Teva Label Information)
  2. Zolpidem: Efficacy and Side Effects for Insomnia (StatPearls/NCBI Bookshelf)
  3. PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness (EMA/PRAC Review Summary)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zolpidem Teva (FAQ)


Q: Is Zolpidem Teva the same thing as Ambien?

A: Zolpidem Teva is a generic medicine containing the active ingredient zolpidem tartrate. This is the exact same active substance found in the brand-name medicine Ambien. Zolpidem Teva is manufactured by Teva Pharmaceuticals and is considered an equivalent, generic formulation.


Q: What is the average time it takes for Zolpidem Teva to start working?

A: Clinical studies show that the immediate-release tablet form of zolpidem is rapidly absorbed by the body. On average, the medicine reaches its highest concentration in the blood approximately 1.6 hours after it is taken. Official guidance instructs that it is taken immediately before bedtime to allow for its intended effect.


Q: Is it common for people to feel groggy or sleepy the next morning after taking this medicine?

A: Official documentation lists next-day somnolence (drowsiness) and dizziness as commonly observed side effects (occurring in 1% to 10% of users). The risk of feeling impaired the next day is increased if a patient does not allow for a full 7 to 8 hours of sleep.


Q: Can elderly patients take Zolpidem Teva safely?

A: Older adults are eligible to use Zolpidem Teva, but its use is conditional. Official prescribing information indicates a lower starting dose is used for this population. Safety warnings also note that older adults may be more sensitive to the drug’s effects, which can increase the risk of side effects like dizziness and potential falls.


Q: Does taking Zolpidem Teva with food change how it works?

A: Yes, taking the tablet with or immediately after a meal may change the medicine's expected action. Regulatory sources note that food can slow the onset of its effects. The medicine is generally recommended to be taken without food for the fastest onset of action.


Q: Is it true that Zolpidem Teva can cause sleepwalking or other sleep behaviors?

A: Regulatory warnings confirm that Zolpidem has been associated with Complex Sleep Behaviors (CSBs). These are rare but serious side effects that include actions like sleep-driving or sleepwalking while not fully awake. A person often has no memory of these events.


Q: Can people develop a dependency on Zolpidem Teva?

A: Yes, official documentation confirms there is a risk of developing drug dependence with this medicine. Because of this risk, treatment is typically limited to the shortest possible duration. Upon stopping the medicine, particularly after prolonged use, there is an established risk of a withdrawal syndrome or the return of sleep problems, known as rebound insomnia.


Q: Can people who have a history of mental health conditions use Zolpidem Teva?

A: Official information states that Zolpidem Teva is not intended to treat a psychotic illness. Official guidance describes that use requires caution in individuals with a history of depression, as pre-existing depression may worsen or new behavioral changes may emerge. Patients with a history of substance abuse also require close supervision.


Q: Can Zolpidem Teva cause temporary memory issues?

A: The medicine has the potential to induce anterograde amnesia, which is difficulty forming new memories while the medicine is active. This side effect is most likely to occur if the patient is awakened prematurely or does not get a full night of sleep, defined as at least 7 to 8 hours.


Q: What do clinical trials say about how many hours of sleep Zolpidem Teva typically adds?

A: Clinical trials examine changes in Total Sleep Time (TST) achieved by participants. Studies conducted for the medicine's approval confirmed that TST measurements observed in the treatment group were measurably different from those in the placebo group during the short-term study periods.


Q: Does my doctor need to know all the vitamins I take before prescribing Zolpidem Teva?

A: Official guidance includes informing a doctor about all products taken, including supplements and herbal products. For example, the herbal product St. John's wort is documented to decrease the effects of the medicine.


Q: Can Zolpidem Teva cause strange dreams or nightmares?

A: Yes, official product documentation lists nightmares as a commonly reported psychiatric disorder during clinical trials. Other related effects listed include hallucinations and confusional states.


Q: Are there any common over-the-counter medicines that should be avoided when taking Zolpidem Teva?

A: Regulatory sources advise caution or avoidance when using Zolpidem Teva with any medicine classified as a CNS depressant (Central Nervous System depressant). This may include certain over-the-counter medications, such as some sedative antihistamines, due to the enhanced risk of extreme drowsiness and impairment.


Q: What happens if I forget to take my dose of Zolpidem Teva?

A: Official patient information states that a forgotten dose should be skipped completely. The medicine must not be taken later in the night. Treatment should then be restarted the next night at the usual time.


Q: How does Zolpidem Teva relate to other medicines used for short-term sleeplessness?

A: Zolpidem Teva is categorized as a Z-drug, a type of sedative-hypnotic agent. This class is distinct from traditional benzodiazepine medicines. Its mechanism is characterized by a more selective binding action at a specific receptor in the brain, which allows for a rapid onset of sleep promotion.


Q: Is there any information about Zolpidem Teva and the use of alcohol?

A: Official regulatory documents state that alcohol use is strictly contraindicated (forbidden) while taking Zolpidem Teva. Alcohol significantly enhances the central depressant effects of the medicine, which increases the risks of severe impairment, falls, and complex sleep behaviors.


Q: Is Zolpidem Teva for people who only have trouble falling asleep?

A: Zolpidem Teva is formally indicated for the short-term management of insomnia characterized by difficulty with sleep initiation (falling asleep). However, clinical studies also explore its effects on sleep maintenance, measuring things like time spent awake after initially falling asleep.


Q: Does this medicine interact with herbal supplements like St. John's Wort or melatonin?

A: The herbal product St. John's wort is listed in official documentation as reducing the effects of Zolpidem Teva. Melatonin is not explicitly named in regulatory warnings, but it is important that all supplements are disclosed to a healthcare professional due to the potential for interactions.


Q: Can Zolpidem Teva affect a person's mood?

A: Official documentation lists certain psychiatric reactions, including agitation, restlessness, and aggression as possible effects. The medicine has also been associated with the worsening of pre-existing depression.


Q: Is a metallic or strange taste in the mouth a known side effect of Zolpidem Teva?

A: Yes, a bitter or metallic taste in the mouth has been included in patient information leaflets from authoritative sources as a possible effect. However, it is not always classified as one of the most common reactions.


Q: Is there a risk of becoming tolerant to the effects of Zolpidem Teva over time?

A: Regulatory text confirms a risk of tolerance development. This means that after repeated use for a period of time, the medicine’s expected effect may be reduced. This potential for tolerance is a key reason why official guidance limits treatment to the shortest possible duration.


Q: What are the documented effects of Zolpidem Teva on balance or coordination?

A: Zolpidem Teva is classified as a CNS depressant that is documented to impair alertness and motor coordination. Common side effects include dizziness, and official warnings note a rare risk of a gait disturbance or increased risk of falls.


Q: Are there specific instructions for what to do in case of a suspected overdose of Zolpidem Teva?

A: Official documentation states that an overdose can lead to symptoms ranging from extreme drowsiness to coma and potentially compromised breathing. Official information advises immediately seeking emergency medical assistance if an overdose is suspected.


Q: What evidence exists regarding Zolpidem Teva's effectiveness in different types of insomnia?

A: The medicine is formally indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation (falling asleep). Its effectiveness has primarily been studied and confirmed in clinical trials focused on this specific symptom.


Q: Does the medicine come with a specific guide or leaflet for patients?

A: Yes, in many jurisdictions, including those regulated by the FDA, the medicine is dispensed with an official Medication Guide or Patient Information Leaflet. This guide provides important detailed safety and use information.


Q: Is the 'Teva' part of the name important, or is it just the manufacturer?

A: The 'Teva' part of the name is the manufacturer's identifier for their specific generic version. It confirms that the medicine contains the active ingredient zolpidem tartrate, which is pharmaceutically equivalent to other versions.


Q: Can Zolpidem Teva cause changes in appetite or weight?

A: Official documentation of adverse reactions lists appetite disorder as an uncommon effect, occurring in 0.1% to 1% of users. Weight decrease is also documented as a rare effect in the official safety profile.


Q: What is the difference between Zolpidem and Zolpidem Tartrate?

A: Zolpidem is the active chemical substance itself. Zolpidem tartrate is the stabilized salt form of the active substance that is contained in the tablets. The tartrate salt is added to improve the product's stability and proper absorption into the body.


Q: What is the purpose of the different release formulations, like extended-release?

A: Zolpidem Teva is an immediate-release tablet primarily aimed at helping with sleep initiation. Other formulations, such as extended-release tablets, are designed to assist with both falling asleep and staying asleep by releasing the medicine into the body over a longer period of time.


Q: Is anxiety listed as a potential side effect of Zolpidem Teva?

A: Yes, official documentation lists anxiety as an infrequent side effect, meaning it occurred in 0.1% to 1% of users during clinical trials. Other listed psychiatric effects include agitation and restlessness.


Q: What are the official guidelines about when a patient should contact their doctor after starting Zolpidem Teva?

A: Official guidance includes information stating that a doctor should be consulted if the symptom being treated (insomnia) persists after 7 to 10 days of using the medicine. This persistence may indicate an underlying medical condition requiring evaluation. Immediate evaluation is also recommended for any new or concerning abnormal thinking or behavioral changes.

Advertisements

How should Zolpidem Teva be stored and disposed of?

How to Store and Dispose of Zolpidem Teva

Official regulatory documents define strict conditions for the storage and disposal of Zolpidem Teva to ensure product quality and public safety.

Storage Component Requirement
Temperature Store at room temperature, typically 20^circ to 25 C (68^circ to 77 F). Do not refrigerate or freeze the medicine.
Protection Keep the medicine in the original package to protect from light and moisture.
Child Safety It is mandatory to keep this medicine out of the sight and reach of children.
Shelf-Life Do not use the medicine after the expiry date (EXP) stated on the carton and blister.
Disposal Unused or expired medicine must not be thrown away via wastewater or household waste. Disposal must be carried out in accordance with local requirements, such as authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolpidem Teva found in:

A-Z Index: